Last reviewed · How we verify

Intermittent bolus of ropivacaine

Henry Ford Health System · FDA-approved active Small molecule Quality 2/100

Intermittent bolus of ropivacaine is a Small molecule drug developed by Henry Ford Health System. It is currently FDA-approved.

Intermittent bolus of ropivacaine, marketed by Henry Ford Health System, holds a niche position in the local anesthetic market with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and safety profile, which supports its use in various surgical procedures. The primary risk is the potential increase in competition post-patent expiry in 2028, which could impact revenue and market share.

At a glance

Generic nameIntermittent bolus of ropivacaine
SponsorHenry Ford Health System
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intermittent bolus of ropivacaine

What is Intermittent bolus of ropivacaine?

Intermittent bolus of ropivacaine is a Small molecule drug developed by Henry Ford Health System.

Who makes Intermittent bolus of ropivacaine?

Intermittent bolus of ropivacaine is developed and marketed by Henry Ford Health System (see full Henry Ford Health System pipeline at /company/henry-ford-health-system).

What development phase is Intermittent bolus of ropivacaine in?

Intermittent bolus of ropivacaine is FDA-approved (marketed).

Related